Pfizer plans to buy Encysive after expiration of antitrust review

NEW YORK Pfizer declared its interest in buying Encysive Pharmaceuticals’ outstanding shares at $2.34 on the news of the expiration of its antitrust waiting period

Shares for Pfizer, according to published reports closed on Wednesday at $20.69, down 9 cents, while Encysive closed at $2.34. Revenue for shares of Pfizer is a reported $48.42 billion in 2007, while Encysive closed the year at $35.92 million.

According to published reports, the offer from Pfizer’s subsidiary Explorer Acquisition to buy shares expires at midnight eastern time, unless it were to be extended for any reason.